Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_3

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 3Large-scale testing

4(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 34 (100.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials

Showing 4 of 4

completedphase_3

Study of NPO-11 in Patients Undergoing Gastrointestinal Endoscopy

NCT03263910

completedphase_3

Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy

NCT00745459

completedphase_3

Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men

NCT00740324

completedphase_3

Phase III Controlled Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy

NCT00742599

Clinical Trials (4)

Showing 4 of 4 trials

NCT03263910Phase 3

Study of NPO-11 in Patients Undergoing Gastrointestinal Endoscopy

Completed

NCT00745459Phase 3

Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy

Completed

NCT00740324Phase 3

Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men

Completed

NCT00742599Phase 3

Phase III Controlled Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4